Dezapelisib Terminated Phase 2 Trials for Refractory Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02456675INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma